Cargando…

Correction: Expansion of mouse castration-resistant intermediate prostate stem cells in vitro

Detalles Bibliográficos
Autores principales:	Xu, Yalan, Mu, Jie, Zhou, Zhixia, Leng, Yu, Yu, Yali, Song, Xiuyue, Liu, Aihua, Zhu, Hai, Li, Jing, Wang, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694920/ https://www.ncbi.nlm.nih.gov/pubmed/36434710 http://dx.doi.org/10.1186/s13287-022-03207-1

Ejemplares similares

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
por: Xu, Yalan, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2022)

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
Publicado: (2014)

Correction: Learning from the “tail end” of de-implementation: the case of chemical castration for localized prostate cancer
por: Skolarus, Ted A., et al.
Publicado: (2023)

Correction: In vitro expansion impaired the stemness of early passage mesenchymal stem cells for treatment of cartilage defects
por: Jiang, Tongmeng, et al.
Publicado: (2019)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Correction: Attractive Interactions among Intermediate Filaments Determine Network Mechanics In Vitro
Publicado: (2014)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

Expanding tubular microvessels on stiff substrates with endothelial cells and pericytes from the same adult tissue
por: Song, Xiuyue, et al.
Publicado: (2022)

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
por: Schultz, Neil M, et al.
Publicado: (2018)

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Correction: Empirical Support for Optimal Virulence in a Castrating Parasite
por: Jensen, Knut Helge, et al.
Publicado: (2009)

Correction: Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2017)

Correction to: The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
por: Tong, Dali
Publicado: (2021)

Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer
por: Jo, Jung Ki, et al.
Publicado: (2018)

Correction: Plasticity of Intermediate Filament Subunits
por: Kirmse, Robert, et al.
Publicado: (2010)

Publisher Correction: An extended cluster expansion for ground states of heterofullerenes
por: Cheng, Yun-Hua, et al.
Publicado: (2019)

Correction: Improvement of a Predictive Model of Castration-Resistant Prostate Cancer: Functional Genetic Variants in TGFβ1 Signaling Pathway Modulation
por: Teixeira, Ana L., et al.
Publicado: (2013)

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment
por: Ziouziou, Hajer, et al.
Publicado: (2018)

Correction: Expansion of Cord Blood CD34(+) Cells in Presence of zVADfmk and zLLYfmk Improved Their In Vitro Functionality and In Vivo Engraftment in NOD/SCID Mouse
Publicado: (2014)

Correction: Mouse Cytoplasmic Dynein Intermediate Chains: Identification of New Isoforms, Alternative Splicing and Tissue Distribution of Transcripts
por: Kuta, Anna, et al.
Publicado: (2010)

Author Correction: Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
por: Daisley, Brendan A., et al.
Publicado: (2020)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
Publicado: (2014)

Correction to: The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway
por: Pak, Sahyun, et al.
Publicado: (2019)

Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
por: Ozyigit, Gokhan, et al.
Publicado: (2019)

Correction: Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion
Publicado: (2015)

Correction: Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate
por: Liu, Weiyong, et al.
Publicado: (2022)

Correction: Influenza A Virus Assembly Intermediates Fuse in the Cytoplasm
por: Lakdawala, Seema S., et al.
Publicado: (2016)

Correction to: Divergence in chondrogenic potential between in vitro and in vivo of adipose- and synovial-stem cells from mouse and human
por: Chijimatsu, Ryota, et al.
Publicado: (2021)

Author Correction: The impact of the striped field mouse’s range expansion on communities of native small mammals
por: Tulis, Filip, et al.
Publicado: (2023)

Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
por: Lee, Lui Shiong, et al.
Publicado: (2022)

Correction: Predictive value of intravascular ultrasound for the function of intermediate coronary lesions
por: Zhu, Yajuan, et al.
Publicado: (2023)

Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_731fmfqrn7191sre4qb9fpm9jk